Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rhythm Pharmaceuticals Inc.

101.03
+1.621.63%
Volume:122.27K
Turnover:12.33M
Market Cap:6.74B
PE:-32.53
High:101.98
Open:99.85
Low:99.57
Close:99.41
52wk High:116.00
52wk Low:45.91
Shares:66.74M
Float Shares:53.42M
Volume Ratio:1.41
T/O Rate:0.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1057
EPS(LYR):-4.3376
ROE:-85.79%
ROA:-26.74%
PB:45.31
PE(LYR):-23.29

Loading ...

S&P 500 Futures Up In Premarket Trading; Jazz Pharmaceuticals, Clearwater Analytics Lead

Dow Jones
·
2 hours ago

Rhythm Pharmaceuticals Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Nov 11

Rhythm Pharmaceuticals Reports Setmelanotide Significantly Reduces BMI in Hypothalamic Obesity Phase 3 Trial

Reuters
·
Nov 10

Rhythm Pharmaceuticals price target raised to $114 from $105 at Canaccord

TIPRANKS
·
Nov 10

Analysts’ Top Healthcare Picks: Rhythm Pharmaceuticals (RYTM), Eli Lilly & Co (LLY)

TIPRANKS
·
Nov 10

Rhythm Pharmaceuticals Is Maintained at Buy by Needham

Dow Jones
·
Nov 08

Sector Update: Health Care Stocks Retreat Friday Afternoon

MT Newswires Live
·
Nov 08

BUZZ-U.S. STOCKS ON THE MOVE-Novo Nordisk, Block, Peloton Interactive

Reuters
·
Nov 08

BUZZ-U.S. STOCKS ON THE MOVE-ANI Pharmaceuticals, Wendy's, nLIGHT

Reuters
·
Nov 07

BUZZ-Rhythm falls after US FDA delays decision on drug for brain damage-related obesity

Reuters
·
Nov 07

Rhythm Pharmaceuticals Shares Down 3.5% Premarket After US FDA Extends Review of Co's Brain Damage-Related Obesity Drug

THOMSON REUTERS
·
Nov 07

FDA Extends Review of Rhythm Pharmaceuticals' IMCIVREE for Acquired Hypothalamic Obesity

Reuters
·
Nov 07

Rhythm Pharmaceuticals: FDA in Oct Requested Additional Sensitivity Analyses of Efficacy Data From Phase 3 Trial in Acquired Hypothalamic Obesity

THOMSON REUTERS
·
Nov 07

Rhythm Pharmaceuticals Inc: Major Amendment Did Not Include Any Information Relating to Safety or Manufacturing of Setmelanotide

THOMSON REUTERS
·
Nov 07

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for Imcivree® (Setmelanotide) for Patients With Acquired Hypothalamic Obesity

THOMSON REUTERS
·
Nov 07

Rhythm Pharmaceuticals Inc: FDA Sets Updated Pdufa Goal Date of March 20, 2026

THOMSON REUTERS
·
Nov 07

Rhythm Pharmaceuticals Inc - Announces Listing Agreements in Five Canadian Provinces

THOMSON REUTERS
·
Nov 06

Rhythm Pharmaceuticals Announces Public Reimbursement for Imcivree® (Setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program

THOMSON REUTERS
·
Nov 06

Rhythm Pharmaceuticals Secures Public Reimbursement for IMCIVREE in Five Canadian Provinces and Under NIHB Program

Reuters
·
Nov 06

Stock Track | Rhythm Pharmaceuticals Plummets 5.65% Following Oppenheimer Downgrade

Stock Track
·
Nov 05